A team of international researchers developed a deep-learning system to screen patients for diabetic retinopathy and related eye diseases, according to a study published in JAMA Dec. 12. The ...

Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...

LEWES, Del., Oct. 1, 2025 /PRNewswire/ -- Neteera Technologies Ltd. today announced results from a clinical study demonstrating that its contactless monitoring system achieved 77% sensitivity in ...

n = number of patients included in each study group for safety and tolerability assessments Abbreviations: EOS: End of Study (week 16); BID: twice daily; CBD: cannabidiol; QD: once daily. Of the DHT ...

Researchers say the results are encouraging but also shared cautions. More than half of children in early stages of an ongoing study were able to eat a food they were allergic to one year after ...

Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...

n = number of patients included in each study group for HbA1c and body weight efficacy assessments Abbreviations: EOS: End of Study (week 16); Wk: week; BID: twice daily; CBD: cannabidiol; QD: once ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus ® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus ® Recent financings ...

While weight gain is not seen as an issue in kids, more and more studies are showing that it should be an issue. Usually ...